This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (56)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Osteoporosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael R. McClung, MD; Javier San Martin, MD; Paul D. Miller, MD; Roberto Civitelli, MD; Francisco Bandeira, MD; Molly Omizo, MD; David W. Donley, PhD; Gail P. Dalsky, PhD; Erik F. Eriksen, MD

Arch Intern Med. 2005;165:1762-1768.

Background  Antiresorptive agents for the treatment of osteoporosis suppress bone remodeling and reestablish bone turnover at a lower rate to reduce bone loss. Recombinant teriparatide (human parathyroid hormone 1-34) stimulates bone formation, increases bone mass, and improves bone microarchitecture. We contrasted the effects of once-daily doses of 20 µg of teriparatide and 10 mg of alendronate sodium on bone mineral density (BMD) and markers of bone turnover.

Methods  Markers of bone turnover and areal BMD were assessed in 203 postmenopausal women with osteoporosis in an 18-month randomized parallel double-blind study; volumetric BMD was measured in a subset of women.

Results  Teriparatide significantly increased markers of bone turnover that peaked at 6 months (serum procollagen type I N-terminal propeptide, 218%, and urinary N-telopeptide corrected for creatinine, 58%; P<.001); alendronate significantly decreased the markers at 6 months (–67% and –72%, respectively; P<.001). At 18 months, areal and volumetric spine BMDs were significantly higher with teriparatide than with alendronate (10.3% vs 5.5% [P<.001] and 19.0% vs 3.8% [P<.01], respectively). Areal femoral neck BMD was significantly higher than baseline in the teriparatide and alendronate groups (3.9% and 3.5%, respectively). There were no significant differences in trabecular femoral neck BMD between the teriparatide and alendronate groups (4.9% and 2.2%, respectively). Cortical volumetric femoral neck BMD was significantly different between the teriparatide and alendronate groups (–1.2% and 7.7%, respectively; P = .05).

Conclusion  Two distinct options for the management of osteoporosis lead to increases in BMD by opposite mechanisms of action on bone remodeling.

Author Affiliations: Oregon Osteoporosis Center, Providence Portland Medical Center, Portland (Drs McClung and Omizo); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind (Drs San Martin, Donley, Dalsky, and Eriksen); Colorado Center for Bone Research, Lakewood (Dr Miller); Barnes-Jewish Hospital, Washington University School of Medicine, St Louis, Mo (Dr Civitelli); and Osteoporosis Center, University of Pernambuco, and Hospital Agamenon Magalhaes, Recife, Brazil (Dr Bandeira).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quantitative Radionuclide Studies of Bone
Blake et al.
JNM 2009;50:1747-1750.
FULL TEXT  

Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture
Mulgund et al.
Therapeutic Advances in Musculoskeletal Diseases 2009;1:5-11.
ABSTRACT  

Denosumab in postmenopausal osteoporosis: what the clinician needs to know
Lewiecki
Therapeutic Advances in Musculoskeletal Diseases 2009;1:13-26.
ABSTRACT  

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Cosman et al.
J. Clin. Endocrinol. Metab. 2009;94:3772-3780.
ABSTRACT | FULL TEXT  

Effects of Teriparatide Retreatment in Osteoporotic Men and Women
Finkelstein et al.
J. Clin. Endocrinol. Metab. 2009;94:2495-2501.
ABSTRACT | FULL TEXT  

Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black et al.
J. Clin. Endocrinol. Metab. 2008;93:2166-2172.
ABSTRACT | FULL TEXT  

Teriparatide in the treatment of osteoporosis
Stroup et al.
Am J Health Syst Pharm 2008;65:532-539.
ABSTRACT | FULL TEXT  

Response to Teriparatide in Patients with Baseline 25-Hydroxyvitamin D Insufficiency or Sufficiency
Dawson-Hughes et al.
J. Clin. Endocrinol. Metab. 2007;92:4630-4636.
ABSTRACT | FULL TEXT  

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag et al.
NEJM 2007;357:2028-2039.
ABSTRACT | FULL TEXT  

Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men
Finkelstein et al.
J. Clin. Endocrinol. Metab. 2006;91:2882-2887.
ABSTRACT | FULL TEXT  

Parathyroid hormone for the treatment of osteoporosis: a systematic review.
Cranney et al.
CMAJ 2006;175:52-59.
ABSTRACT | FULL TEXT